Brentuximab Vedotin is an anti-CD30 antibody approved by the FDA in relapsed and refractory CD30+ PTCL, as recently the ECHELON-2 trial showed a statistical improvement in the response rate for 83% of patients. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.